Home › Funds › Farallon Capital Management › DYN
Farallon Capital Management position in DYN
DYNE THERAPEUTICS INC · Health Care
Latest position (Q1 2026)10.00K sh
Reported value held$181.30K
Portfolio Weight0.00%
First reportedQ2 2024
Last changeHold
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q2 2024 | 6.00K | $211.74K | New |
| Q3 2024 | 428.00K | $15.37M | Add |
| Q4 2024 | 229.12K | $5.40M | Reduce |
| Q1 2025 | 10.00K | $104.60K | Reduce |
| Q2 2025 | 10.00K | $95.20K | Hold |
| Q3 2025 | 10.00K | $126.50K | Hold |
| Q4 2025 | 10.00K | $195.60K | Hold |
| Q1 2026 | 10.00K | $181.30K | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
Other funds holding DYN
- BlackRock Inc 12.40M sh · $275.50M · Q2 2026
- Fidelity Management & Research (FMR) 11.21M sh · $248.91M · Q2 2026
- Janus Henderson Group 13.65M sh · $247.43M · Q1 2026
- Vanguard Group 11.22M sh · $219.38M · Q4 2025
- Geode Capital Management 3.74M sh · $83.16M · Q2 2026
- JPMorgan Chase & Co 3.15M sh · $67.15M · Q2 2026
- Bank of America Corp 2.23M sh · $49.60M · Q2 2026
- Goldman Sachs Group 2.16M sh · $47.91M · Q2 2026
- Franklin Resources 2.03M sh · $45.10M · Q2 2026
- Marshall Wace 1.49M sh · $33.07M · Q2 2026
- Northern Trust Corp 1.28M sh · $28.39M · Q2 2026
- Charles Schwab Investment Management 1.20M sh · $26.70M · Q2 2026